MK 677 vs CJC 1295: compare oral ghrelin agonists and injectable GHRH analogs, their half-lives, GH release patterns, side effects, and FDA status.
MK 677 and CJC 1295 both aim to raise growth hormone, but they work through completely different mechanisms. MK 677 (ibutamoren) is an oral ghrelin-receptor agonist that signals the pituitary to release more growth hormone, while CJC 1295 is an injectable growth hormone-releasing hormone (GHRH) analog that amplifies the body's own GH pulses. Neither compound is FDA-approved for human use in the United States, and both are sold strictly as research chemicals.
When researchers weigh cjc 1295 vs mk 677, the practical trade-off is usually convenience versus precision: a daily oral capsule that increases appetite, or a subcutaneous injection that mimics a natural hormone signal.
What Is MK 677?
MK 677, also called ibutamoren, is a non-peptide molecule that binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. Because it mimics ghrelin, it triggers GH release alongside a pronounced increase in appetite.
Researchers evaluating MK 677 typically note these traits:
- Oral bioavailability: it survives digestion, so no injection is required.
- Half-life: roughly 4 to 6 hours, with IGF-1 staying elevated for up to 24 hours.
- GH pattern: a broad, sustained rise rather than sharp pulses.
- Downstream markers: IGF-1 increases, and some users report higher fasting glucose, water retention, and lethargy.
Doses discussed in research communities usually land between 10 mg and 25 mg per day, but no human dosing standard exists. Long-term human safety data for MK 677 is limited, and it is not approved for any medical use.
What Is CJC 1295?
CJC 1295 is a synthetic GHRH analog built from a modified fragment of GRF(1-29). It binds GHRH receptors in the pituitary and amplifies the pulsatile release of growth hormone that the body already produces.
Two versions behave very differently:
- CJC 1295 with DAC: a Drug Affinity Complex binds the peptide to albumin, extending its half-life to roughly 6 to 8 days.
- CJC 1295 without DAC: often labeled Mod GRF 1-29, with a half-life near 30 minutes, which keeps the pulse pattern closer to normal.
CJC 1295 must be injected subcutaneously because it is not orally bioavailable. It is most often researched alongside a growth hormone-releasing peptide such as ipamorelin to build a stronger, more physiological GH pulse.
MK 677 vs CJC 1295: Side-by-Side
| Feature | MK 677 | CJC 1295 |
|---|---|---|
| Administration | Oral capsule or liquid | Subcutaneous injection |
| Mechanism | Ghrelin receptor agonist (GHS-R1a) | GHRH receptor agonist |
| Half-life | 4 to 6 hours | About 30 minutes without DAC; 6 to 8 days with DAC |
| GH release pattern | Broad and sustained | Amplifies natural pulses |
| Appetite | Strongly increased | Minimal change |
| IGF-1 elevation | Yes | Yes |
| Cortisol and prolactin | May increase | Generally minimal |
| Discussed research dose | 10 to 25 mg daily | 1 to 2 mg weekly with DAC, or 100 to 300 mcg two to three times daily without DAC |
| FDA status | Not approved for human use | Not approved for human use |
The clearest single takeaway is that MK 677 raises growth hormone in a broad, sustained pattern, while CJC 1295 amplifies the body's natural pulses. MK 677 also commonly increases appetite, and CJC 1295 generally does not.
Where the Two Compounds Overlap
Both compounds ultimately raise IGF-1, which is why they appear in the same discussions about body composition, recovery, and sleep quality. MK 677 turns on the ghrelin receptor, while CJC 1295 activates the GHRH receptor.
Because those receptors use separate signaling routes, many researchers study them together. Combining a GHRH analog with a ghrelin agonist is generally described as synergistic, producing a larger GH pulse than either compound alone. That overlap is also why searches such as cjc 1295 ipamorelin vs mk 677 are so common, since ipamorelin fills the ghrelin-agonist role in the injectable stack.
CJC 1295 With DAC vs Without DAC
The version of CJC 1295 you compare against matters. Someone asking about cjc 1295 dac vs mk 677 is usually weighing a long-acting weekly injection against a daily oral capsule.
| Feature | CJC 1295 with DAC | CJC 1295 without DAC |
|---|---|---|
| Half-life | 6 to 8 days | About 30 minutes |
| Injection frequency | Once or twice weekly | Two to three times daily |
| GH pattern | Near-continuous elevation | Short, natural pulses |
| IGF-1 effect | Steady and sustained | Pulse-driven |
CJC 1295 with DAC produces a near-continuous elevation in GH and IGF-1, which some researchers argue is less physiological than pulsatile release. The non-DAC version is shorter-acting and needs more frequent injections, but it preserves a more natural rhythm.
Reported Side Effects and Safety Considerations
Neither compound has completed large, long-term human trials, so safety information comes mostly from small studies and user reports.
- MK 677: intense hunger, water retention, fatigue, elevated fasting blood sugar, and possible increases in cortisol and prolactin. Insulin resistance is a recurring concern in longer-use reports.
- CJC 1295: injection-site irritation, flushing, headache, and mild water retention. The DAC form may blunt the body's natural GH pulsatility.
- Both: not FDA-approved, not for human consumption, and not a substitute for medical care. Anyone considering these compounds should talk with a healthcare professional first.
Other Peptides Researchers Compare
GH secretagogues are only part of this research space. Fat-metabolism compounds appear in the same searches, which is why queries like aod-9604 vs cjc-1295 ipamorelin show up alongside them. AOD-9604 is a modified fragment of human growth hormone studied for lipolysis, while CJC 1295 paired with ipamorelin targets the GH and IGF-1 axis. The two approaches are not interchangeable, and combining them is not well studied.
How to Choose Between Them for Research
- Pick MK 677 if oral administration is the priority and increased appetite is acceptable or even useful.
- Pick CJC 1295 if a pulsatile, hormone-like GH signal is the goal and injections are acceptable.
- Consider pairing CJC 1295 with a GHRP only when a study design calls for a stronger combined signal and glucose monitoring is in place.
A mk 677 vs cjc-1295 comparison ultimately comes down to route of administration and how much appetite stimulation a research design can tolerate. MK 677 changes appetite, glucose, and cortisol in ways CJC 1295 does not, and CJC 1295 requires injection in ways MK 677 does not. Neither option is a proven human therapy.
Frequently Asked Questions
Is MK 677 or CJC 1295 better for building muscle?
There is no head-to-head human trial comparing them for muscle growth, and neither is FDA-approved for that purpose. Both raise IGF-1 in research settings through different receptors, so responses are likely to vary by individual, dose, and duration. MK 677 also drives appetite and can affect blood sugar, which many people consider a drawback rather than a benefit.
Can you stack MK 677 with CJC 1295?
Some researchers combine them because one activates the ghrelin receptor and the other activates the GHRH receptor, which can produce a larger GH pulse than either alone. However, no clinical trials have evaluated the combination in humans, and both compounds can raise IGF-1 and affect glucose metabolism. Stacking increases the unknowns and should only be discussed with a qualified healthcare professional.
Does MK 677 shut down your natural growth hormone production?
MK 677 does not suppress the GH axis the way injected growth hormone can, because it stimulates the pituitary rather than replacing its output. That said, chronic ghrelin-receptor stimulation may alter receptor sensitivity over time, and long-term human data is essentially absent. Anyone concerned about hormonal effects should get medical guidance rather than self-experimenting.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.